Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 15Myelodysplastic Syndromes 3Myeloproliferative Disorders 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Sarcoma, Myeloid 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Azacitidine 2aldesleukin 1Whole-Body Irradiation 1Vorinostat 1Peripheral Blood Stem Cell Transplantation 1Idarubicin 1Gemtuzumab 1Filgrastim 1Etoposide 1Cytarabine 1Busulfan 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Erythroblastic, Acute × Gemtuzumab × 1 year × Clear all
NCT00658814 2026-05-29

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
133 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡